News

HHS boosts smoking cessation, vaccinations with $137 million to states

BY Michael Johnsen

WASHINGTON — The U.S. Department of Health and Human Services on Thursday awarded $137 million to states to boost prevention and public health initiatives, including support for smoking-cessation programs and vaccinations.

Awarded in nearly every state, the grants enhance state, tribal, local and territorial efforts to provide tobacco cessation services, strengthen public health laboratory and immunization services, prevent healthcare-associated infections, and provide comprehensive substance abuse prevention and treatment.

“More than ever, it is important to help states fight disease and protect public health,” stated HHS secretary Kathleen Sebelius. “These awards are an important investment and will enable states and communities to help Americans quit smoking, get immunized and prevent disease and illness before they start.”

The awards include nearly $5 million to help states and territories enhance and expand the national network of tobacco cessation quit-lines to increase the number of tobacco users who quit. Quit-lines are the toll-free numbers people can call to obtain smoking-cessation treatments and services. And more than $42 million has been earmarked to support improvements to the Immunization Information Systems (registries) and other immunization information technologies, the development of systems to improve billing for immunization services, the planning and implementation of adult immunization programs, the enhancement of vaccination capacity located in schools, and evaluations of the impact on disease of recent vaccine recommendations for children and adolescents.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Dove, MTV team up to bring up-and-coming female DJs center stage

BY Antoinette Alexander

ENGLEWOOD CLIFFS, N.J. — Female DJs are the newest trendsetters for what is hot in music, style and pop culture, and Unilever’s Dove Go Fresh deodorant and body mist and MTV are spotlighting three up-and-coming DJs in a new video series, titled "Dove Fresh Spin," in an effort to bring this emerging set of style mavens to women everywhere.

These real female DJs — Jessica Who, Chelsea Leyland and Diamond Kuts — are giving viewers an exclusive behind-the-scenes look at their lives as DJs and as cultural “insiders” as they uncover the ultimate in freshness.

Dove Go Fresh and MTV have created the "Dove Fresh Spin" video series, where DJs Jessica Who, Chelsea Leyland and Diamond Kuts bring trend seekers into their inner circle, sharing personal stories, style secrets and music insights gathered by having their finger on the pulse of all that is cool. Putting new Dove Go Fresh rebalance deodorant and body mist to the test on the red carpet, these 20-something DJs will be on-site as arbiters of what is cool and fresh at the 2011 MTV Video Music Awards, New York Fashion Week and ‘O’ Music Awards. Fans across the country can follow the Dove Go Fresh DJs by tuning into MTV or logging onto Dove.mtv.com to see the video series.

The three DJs made their debuts with MTV at the annual pre-VMA tour, held July 28 through Aug. 5, and will make appearances at the mtvU Campus Invasion Tour in October. While on tour, they will be spinning at local stops around the country and greeting music fans face-to-face.

Dove Go Fresh rebalance deodorant and body mist are the newest additions to the Dove collection. With a plum and floral sakura blossom scent, Dove Go Fresh rebalance antiperspirant/deodorant promises to offer 24-hour odor and wetness protection. Dove Go Fresh deodorants and body mists now are offered in five crisp, nature-inspired fragrances that are available in food, drug, mass and club retailers.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

J&J drug approved for chronic pain

BY Alaric DeArment

RARITAN, N.J. — The Food and Drug Administration has approved a drug made by Johnson & Johnson for treating chronic pain, a J&J subsidiary said Friday.

The FDA approved Janssen Pharmaceuticals’ Nucynta ER (tapentadol) tablets, an extended-release drug for moderate to severe chronic pain in adults for whom a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

According to the Centers for Disease Control and Prevention and the American Pain Foundation, more than 42 million Americans ages 20 years and older have chronic pain, making it the most common cause of long-term disability.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?